These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes. Orive G; Emerich D; Khademhosseini A; Matsumoto S; Hernández RM; Pedraz JL; Desai T; Calafiore R; de Vos P Trends Biotechnol; 2018 Apr; 36(4):445-456. PubMed ID: 29455936 [TBL] [Abstract][Full Text] [Related]
3. Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye. Belhaj M; Annamalai B; Parsons N; Shuler A; Potts J; Rohrer B J Vis Exp; 2020 Mar; (157):. PubMed ID: 32281978 [TBL] [Abstract][Full Text] [Related]
4. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Agrahari V; Agrahari V; Mandal A; Pal D; Mitra AK Expert Opin Drug Deliv; 2017 Oct; 14(10):1145-1162. PubMed ID: 27967247 [TBL] [Abstract][Full Text] [Related]
5. Encapsulated cell technology: Delivering cytokines to treat posterior ocular diseases. Wang J; Fan W; Liu B; Pu N; Wu H; Xue R; Li S; Song Z; Tao Y Pharmacol Res; 2024 May; 203():107159. PubMed ID: 38554790 [TBL] [Abstract][Full Text] [Related]
6. Ocular drug delivery system: a reference to natural polymers. Pahuja P; Arora S; Pawar P Expert Opin Drug Deliv; 2012 Jul; 9(7):837-61. PubMed ID: 22703523 [TBL] [Abstract][Full Text] [Related]
7. Stem cell treatment of degenerative eye disease. Mead B; Berry M; Logan A; Scott RA; Leadbeater W; Scheven BA Stem Cell Res; 2015 May; 14(3):243-57. PubMed ID: 25752437 [TBL] [Abstract][Full Text] [Related]
8. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268 [TBL] [Abstract][Full Text] [Related]
9. Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications. Kang-Mieler JJ; Dosmar E; Liu W; Mieler WF Expert Opin Drug Deliv; 2017 May; 14(5):611-620. PubMed ID: 27551742 [TBL] [Abstract][Full Text] [Related]
10. Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics. Pagels RF; Prud'homme RK J Control Release; 2015 Dec; 219():519-535. PubMed ID: 26359125 [TBL] [Abstract][Full Text] [Related]
13. Drug delivery systems for the eye. Kearns VR; Williams RL Expert Rev Med Devices; 2009 May; 6(3):277-90. PubMed ID: 19419285 [TBL] [Abstract][Full Text] [Related]
14. Perspectives on the interface of drug delivery and tissue engineering. Ekenseair AK; Kasper FK; Mikos AG Adv Drug Deliv Rev; 2013 Jan; 65(1):89-92. PubMed ID: 23000743 [TBL] [Abstract][Full Text] [Related]
15. [Drug delivery to target the posterior segment of the eye]. Behar-Cohen F Med Sci (Paris); 2004; 20(6-7):701-6. PubMed ID: 15329823 [TBL] [Abstract][Full Text] [Related]
16. Drug delivery to the posterior segment of the eye. Fischer N; Narayanan R; Loewenstein A; Kuppermann BD Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325 [TBL] [Abstract][Full Text] [Related]
17. The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. Herrero-Vanrell R; Bravo-Osuna I; Andrés-Guerrero V; Vicario-de-la-Torre M; Molina-Martínez IT Prog Retin Eye Res; 2014 Sep; 42():27-43. PubMed ID: 24819336 [TBL] [Abstract][Full Text] [Related]
18. [Review of approaches to cell therapy in ophthalmology]. Subbot AM; Kasparova EA; Subbot AM; Kasparova EA Vestn Oftalmol; 2015; 131(5):74-81. PubMed ID: 26845876 [TBL] [Abstract][Full Text] [Related]
19. Mounting of Biomaterials for Use in Ophthalmic Cell Therapies. Harkin DG; Dunphy SE; Shadforth AMA; Dawson RA; Walshe J; Zakaria N Cell Transplant; 2017 Nov; 26(11):1717-1732. PubMed ID: 29338382 [TBL] [Abstract][Full Text] [Related]